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Abstract
Breast cancer is the most common cancer in women in developed countries, and the contribution of genetic susceptibility
to breast cancer development has been well-recognized. However, a great proportion of these hereditary predisposing
factors still remain unidentified. To examine the contribution of rare copy number variants (CNVs) in breast cancer
predisposition, high-resolution genome-wide scans were performed on genomic DNA of 103 BRCA1, BRCA2, and PALB2
mutation negative familial breast cancer cases and 128 geographically matched healthy female controls; for replication an
independent cohort of 75 similarly mutation negative young breast cancer patients was used. All observed rare variants
were confirmed by independent methods. The studied breast cancer cases showed a consistent increase in the frequency of
rare CNVs when compared to controls. Furthermore, the biological networks of the disrupted genes differed between the
two groups. In familial cases the observed mutations disrupted genes, which were significantly overrepresented in cellular
functions related to maintenance of genomic integrity, including DNA double-strand break repair (P=0.0211). Biological
network analysis in the two independent breast cancer cohorts showed that the disrupted genes were closely related to
estrogen signaling and TP53 centered tumor suppressor network. These results suggest that rare CNVs represent an
alternative source of genetic variation influencing hereditary risk for breast cancer.
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Introduction
Breast cancer is the most common malignancy affecting women.
It is a complex disease with a well-established genetic component
[1]; however, most of the familial and young breast cancer cases still
remain unexplained by inherited mutations in the known suscep-
tibility genes [2]. Multiple genome-wide association studies (GWAS)
have identified several breast cancer associated single nucleotide
polymorphisms (SNPs), but these have only modest effect sizes and
explain much less of the heritability than originally anticipated [3].
Consequently, the contribution of rare variants with moderate to
even high disease penetrance is now beginning to be more widely
accepted. With the exception of some specific founder mutations,
these rare variants are individually infrequent, and even specific to
single cases or families. Much of the work with rare genomic
variants has been conducted through candidate gene re-sequencing
studies mainly concentrating on DNA damage response genes,
Fanconi anemia/BRCA pathway genes in particular, and their
coding region variations [2]. However, rare genomic microduplica-
tions and microdeletions, also known as structural variants or copy
number variants (CNVs), could represent an alternative class of
genetic variation responsible for increased cancer risk.
Recent reports have suggested a role for genomic structural
variants in susceptibility to various diseases, particularly neurode-
velopmental disorders [4,5]. Association of common CNVs with
breast cancer susceptibility has been ruled out by a recently
performed large case-control study [6], but the contribution of
rare CNVs still remains poorly explored. As alleles in this variation
class will be individually rare, the studies remain statistically
underpowered to identify any specific loci involved, but the overall
involvement can be tested by comparing the collective frequency
of rare variants in cases with that in controls [5]. Moreover, the
functional profiling of the disrupted genes will have a potential to
reveal biological processes, which when defective could predispose
to breast cancer. The known susceptibility genes are already
considered to cause cancer predisposition through different
mechanisms. Whereas BRCA1 and BRCA2 function in DNA
repair [7], other high-risk susceptibility genes, TP53 and PTEN,
participate in cell cycle control and regulation of cell proliferation
[8,9].
Here we have examined whether rare CNVs throughout the
genome display an increased frequency in familial and young
breast cancer cases when compared to healthy controls, and
whether the biological pathways or processes, to which the
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provide evidence that rare CNVs contribute to breast cancer
susceptibility and that the disrupted genes are closely related to the
TP53 tumor suppression network and to estrogen signaling.
Results
Rare CNV discovery in breast cancer cases and controls
Genome-wide scans for structural variants were performed on
103 familial breast cancer cases and 128 controls, using high-
resolution Illumina HumanOmni1-Quad BeadChips. Stringent
quality control criteria were applied to ensure that ascertainment
of CNVs was consistent between cases and controls. The
frequencies of common CNVs were monitored in both groups,
and their frequency did not significantly differ (mean 9.7 CNVs
for cases and 9.13 CNVs for controls). Rare variants were defined
as those that did not overlap over 60% with the common CNVs
in Toronto Database of Genomic Variants, and all CNVs
fulfilling the rare variant criteria were confirmed by independent
method. In the studied 231 subjects we observed 65 microdele-
tions and microduplications, ranging in size from 25 kb to
612 kb. In cases, there were 15 deletions (mean length 123 kb,
median 61 kb) and 20 duplications (mean 216 kb, median
173 kb), whereas in controls 14 deletions (mean 146 kb, median
133 kb) and 16 duplications (mean 242 kb, median 186 kb) were
observed.
Among familial breast cancer cases the total number of rare
CNVs was slightly higher than in controls: their proportion was
also higher when only considering those rare CNVs involving
genes, and those directly disrupting genes. This trend stayed the
same when analyzing the independent young breast cancer
cohort of 75 patients (Table 1). The difference was most profound
when considering CNVs disrupting genes and restricting the
analysis to variants not shared between cases and controls.
Familial cases showed almost twice, and young breast cancer
cases 1.5 times the number of rare CNVs compared to controls,
but none of the differences were statistically significant. The genes
within each rare CNV locus were identified (Tables S1, S2 and
S3), and functions and pathways of the involved genes (Table S1)
were assessed by using the Ingenuity Pathway Analysis (IPA)
classification system.
Genes disrupted in familial cases show enrichment in
genomic integrity maintenance functions and diabetes
Analyses were restricted to genes, which were either disrupted
by the breakpoints or deleted entirely, as mutations disrupting only
part of the gene are likely to have biological consequences, and
entirely deleted genes in the case of tumor suppressors follow the
rationale of Knudson’s two hit model or haploinsufficiency [10].
Only a few of the disrupted genes were part of known canonical
pathways, and neither cases nor controls showed significant
increase in any of them. The genes disrupted in familial cases
showed, however, a significant overrepresentation in functions
involving the maintenance of genomic integrity (Table 2), whereas
no particular functions were overrepresented among controls.
Three of the genes disrupted in cases were directly involved in
double-strand break (DSB) repair signaling: BLM participates in
BRCA1-mediated DNA damage response [11], RECQL4 is
involved in DNA replication and DSB repair [12], and
DCLRE1C operates in DSB repair by non-homologous end
joining [13]. Both BLM and RECQL4 are RecQ family DNA
helicases with an integral role in the maintenance of genomic
stability. Their defects result in recessive cancer predisposition
syndromes, Bloom and Rothmund-Thompson syndrome, respec-
tively [14,15]. DCLRE1C encodes ARTEMIS, which is essential
for V(D)J recombination. Biallelic mutations result in severe
combined immunodeficiency (SCID), in which lymphoma has
been described [16]. Curiously, the currently observed DCLRE1C
allele is one of the most frequent mutations reported among SCID
patients. This null allele comprises a gross deletion of exons 1–4
and the adjacent MEIG1 gene and results from homologous
recombination of DCLRE1C with the pseudo-DCLRE1C gene,
located 61.2 kb upstream [17]. Based on their biological functions
BLM, RECQL4 and DCLRE1C all represent attractive susceptibility
genes, although to date clearly deleterious, breast cancer related
mutations have not been reported in any of them. Although not
significantly overrepresented, it should be noted, however, that
another DNA repair gene, MCPH1, was found to be disrupted in
one of the studied controls. MCPH1 is an early DNA damage
responsive protein, the dysfunction of which leads to recessive
primary microcephaly without any reported malignancies [18].
The observed CNV deletes exon 13 and is predicted to lead to out
of frame translation of the last exon, number 14, thereby
disrupting one of the three BRCT domains of MCPH1. The
carrier was still healthy at the age of 59 years, supporting the
previous notion that all DNA damage response gene deficiencies
do not necessarily predispose to malignancy.
The genes disrupted in familial cases were also highly
overrepresented among genes connected to diabetes mellitus
(P=0.000268); this connection was mediated mainly through SNP
associations observed in GWAS [19]. This overrepresentation was
also seen in the young breast cancer cohort (P=0.0246), but not in
controls. Of the 16 diabetes associated genes 6 were under b-
estradiol regulation.
Network analysis reveals TP53 and b-estradiol centered
networks in breast cancer cases
The strict pathway-based approach has several limitations as the
function of many genes is currently unknown and cannot be
assigned to any predetermined pathways [20]. Consequently, we
next analyzed IPA networks, which map the biological relation-
ships of the uploaded genes. Curiously, analysis with familial cases
revealed a network centered on TP53 and b-estradiol (score 29).
The same TP53 and b-estradiol centered network was observed
when analyzing genes disrupted in the young breast cancer cohort
Author Summary
Although genetic susceptibility to breast cancer has been
well-established, the majority of the predisposing factors
still remain unidentified. Here, we have taken advantage of
recent technical and methodological advances to examine
the role of a new class of genomic variation, rare copy
number variants (CNVs), in hereditary predisposition to
breast cancer. By examining 103 BRCA1/2 and PALB2
mutation negative familial and 75 young breast cancer
cases, together with 128 geographically matched healthy
female controls, we show that the frequency of rare CNVs
is increased in cases when compared to controls and that
the genes disrupted in individuals of specifically the two
case groups are closely related to estrogen signaling and
TP53 centered tumor suppressor network. The variety of
disrupted genes belonging to these networks underscores
that diverse mechanisms are likely to be relevant to breast
cancer pathogenesis. The current results warrant the
investigation of rare CNVs as new susceptibility factors in
other cancer types as well.
Rare CNVs Contribute to Hereditary Cancer Risk
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together the network with the highest scores (35, 31) centered on
TP53, b-estradiol and CTNNB1 (encoding b–catenin, the onco-
genic nuclear accumulation of which occurs in several malignan-
cies, including breast cancer [21]) and the other around b-estradiol
(Figure 1, Table 3). Neither the TP53 nor b-estradiol centered
network was observed in controls, strongly arguing in favour of the
possibility that dysregulation of these networks is disease related.
The TP53 centered network appears to have obvious tumor
suppressive function, as p53 itself is a key regulator in preventing
cells from malignancy. Somatic TP53 mutations occur frequently
in human malignancies, and germline lesions associate with the
cancer prone Li-Fraumeni syndrome [22]. In the studied breast
cancer cases, six genes disrupted by the observed rare CNVs were
directly linked to TP53 (Figure 1A), and all encode proteins
functioning in pathways with a potential role in malignancy
prevention. Two of these, RECQL4 and BLM, were DNA
damage response proteins. Network interactions were based on the
repression of RECQL4 transcription by p53 [23], and the
requirement of BLM for p53 localization to stalled replication
forks [24]. The other four interactions were based on direct
binding of p53 with HECW2 [25], DAB2IP and EIF2C2 [26]; for
CASP3 p53 has been shown to increase its activation [27]. The
HECW2 disrupting allele was observed in two familial cases,
whereas the others were all singletons (Table S1).
The other network indicated in both of the studied breast
cancer case cohorts centered on b-estradiol (Figure 1A and 1B),
which is the primary biologically active form of estrogen. Exposure
to both exogenous and endogenous estrogens is a well-established
risk factor for breast cancer, and disruptions in estrogen signaling
and metabolism have a potential to affect this risk. The
physiological effects of estrogens are mediated by their ability to
alter the expression of their target genes. Estrogens play a key role
in proliferation and differentiation of healthy breast epithelium,
but also contribute to the progression of breast cancer by
promoting the growth of transformed cells [28]. Many of the
estrogen actions are mediated by intracellular estrogen receptors
ESR1 and ESR2 [29]. The b-estradiol centered network consisted
of several b-estradiol responsive genes, ANKS1B [30], NXPH1,
MEP1B [31], CASP3 [32] and ACSL1 [31], whereas when
separately tested in IPA none of the genes disrupted in controls
were found to be under b-estradiol regulation. Of the network
genes ESR2, STRN and ANKS1B exhibited recurrent disrupting
alleles among cancer cases (Table S1), emphasizing their potential
role in breast cancer predisposition.
Discussion
The results from our high-resolution genome-wide scans for
structural variants provide evidence that rare CNVs contribute to
breast cancer susceptibility. When compared to controls, the
studied breast cancer cases showed a slight but consistent increase
in the frequency of rare CNVs. The difference was not as
profound as seen in psychiatric disorder studies where the
observed changes, typically involving large genomic regions and
numerous genes, can have very severe effects on patients’
phenotype and many of which are de novo mutations [4,5].
However, in our study the biological networks affected by the
disrupted genes differed between breast cancer cases and controls,
supporting their role in cancer predisposition.
Table 1. Proportion of rare CNVs in breast cancer cases and controls.
All observed rare CNVs Observed rare CNVs, not shared
a
Subjects n All Involving genes
b Disrupting genes
c All Involving genes
b Disrupting genes
c
Familial BC cases 103 0.34 (35/103) 0.29 (30/103) 0.24 (25/103) 0.25 (26/103) 0.20 (21/103) 0.17 (17/103)
Young BC cases 75 0.32 (24/75) 0.24 (18/75) 0.23 (17/75) 0.23 (17/75) 0.15 (11/75) 0.13 (10/75)
Controls 128 0.23 (30/128) 0.21 (27/128) 0.16 (20/128) 0.16 (21/128) 0.14 (18/128) 0.09 (12/128)
BC=breast cancer.
aObserved only in cancer cases, or only in controls.
bThe genomic loci has annotated genes.
cGene disruptions include rare CNVs having breakpoints within the genes or promoter regions, and rare CNVs which delete the involved genes entirely.
doi:10.1371/journal.pgen.1002734.t001
Table 2. Molecular and cellular functions, and diseases and disorders overrepresented among the genes disrupted in familial
breast cancer cases.
Molecular and cellular functions P-values
a Genes involved
Organization of chromosomes 0.0133 BLM, DCLRE1C
Maintenance of telomeres 0.0133 BLM, DCLRE1C
Repair of DNA 0.0178 RECQL4, BLM, DCLRE1C
Double-stranded DNA break repair 0.0211 BLM, DCLRE1C
Quantity of corpus luteum 0.00367 CASP3, ESR2
Diseases and disorders
Diabetes mellitus 0.000268 ACSL1,ANKS1B,ARHGAP39,BLM,CASP3,ESR2,KCNIP4,KLHL1,MARCH6,MLF1IP,RBFOX1,STRN,SYNE2
No particular functions were overrepresented among controls.
aStatistically significant false discovery rate (FDR) adjusted P-values; correction for multiple testing was done using the Benjamini-Hochberg method.
doi:10.1371/journal.pgen.1002734.t002
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overrepresentation in functions involving the maintenance of
genomic integrity. This included DSB repair, which is consistent
with the prevailing paradigm that defects in this pathway
contribute to breast cancer predisposition [2]. The three DSB
repair genes, BLM, RECQL4 and DCLRE1C, disrupted in the case
group all represent attractive breast cancer susceptibility genes.
Moreover, IPA analysis demonstrated that the genes disrupted by
rare CNVs in the studied breast cancer cases formed a network
centered on TP53 and b-estradiol, a notion confirmed in two
independent cohorts. Both networks are coherent and biologically
meaningful, and their identification through the used genome-
wide approach provides strong evidence for a role in breast cancer
predisposition.
TP53 network genes encode proteins functioning in pathways
with potential role in malignancy prevention, including DNA
damage response and apoptosis [25], but also RNA interference
[33]. They all represent attractive susceptibility genes, which could
harbor also other cancer predisposing mutations; thus being
excellent candidates for re-sequencing studies. Of the disrupted
TP53 network genes DAB2IP and CASP3 were particularly
interesting. DAB2IP is a member of the Ras GTPase-activating
gene family and has been reported to act as a tumor suppressor.
Inactivation of DAB2IP by promoter methylation occurs in several
Figure 1. Indication of dysfunction of TP53 and b-estradiol centered network in the studied breast cancer cases. IPA was used to
identify the connection between the genes disrupted in all cases (both familial and the cohort consisting of young breast cancer patients). The
analysis identified two networks with (A) TP53, b-estradiol and CTNNB1 (in green) occupying the central positions, and (B) b-estradiol (in green)
occupying the central position. Genes disrupted in breast cancer cases are coloured with red. Solid lines indicate direct molecular interaction and
dashed lines indicate indirect molecular interaction.
doi:10.1371/journal.pgen.1002734.g001
Table 3. Genes disrupted or deleted entirely in breast cancer cases and involved in TP53 and b-estradiol centered network.
Gene Aberration type Involved exons
a Predicted consequence to transcript
b
BLM disruption promoter dup unknown
EIF2C2 disruption ex2-ex18,39UTR dup unknown
HECW2 disruption promoter, ex1 dup unknown
RECQL4 deletion entire gene null allele
DAB2IP disruption promoter, ex1 del null allele
LRRC14 deletion entire gene null allele
ITGA9 disruption ex19-ex23 del in frame deletion
ACSL1 deletion entire gene null allele
KLHL1 disruption promoter, ex1 del null allele
ESR2 disruption ex2-ex9, 39UTR dup unknown
ARHGAP39 disruption ex12-ex13, 39UTR del premature termination
LRRFIP1 disruption promoter, ex1 dup unknown
CASP3 deletion entire gene null allele
TRPM3 disruption promoter, ex1 dup unknown
KCNIP4 disruption ex6-ex9, 39UTR dup unknown
DCLRE1C disruption promoter, ex1-ex4 del null allele
TRAPPC9 disruption promoter, ex1-ex3 dup unknown
STRN disruption ex14-ex18, 39 UTR dup unknown
PPP1R16A disruption ex6-ex10, 39UTR del premature termination
SYNE2 disruption ex50-ex114, 39UTR dup unknown
MARCH6 disruption ex4-ex26, 39UTR dup unknown
GPT deletion entire gene null allele
MLF1IP deletion entire gene null allele
SEMA4B disruption ex3-ex15, 39UTR dup unknown
RBFOX1 disruption ex11-ex13, 39UTR dup unknown
ANKS1B disruption promoter, ex1 dup unknown
NXPH1 disruption promoter, ex1-ex2 del null allele
MEP1B deletion entire gene null allele
Disruption=the gene is disrupted by the CNV breakpoints; deletion=the entire gene is deleted. del=partial gene deletion; dup=partial gene duplication.
aBased on human genome assembly 19 (February 2009).
bAlthough detailed effects of partial gene duplication to gene transcription are not clear, duplication have potential to disrupt transcription by several mechanisms,
such as transcriptional read-through. This can occur by tandem duplication, where gene silencing can be induced by a partially duplicated (39 deleted) version of the
gene itself [54].
doi:10.1371/journal.pgen.1002734.t003
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been shown to modulate epithelial-to-mesenchymal transition and
prostate-cancer metastasis [35]. CASP3 is an apoptosis related
gene, which encodes a member of a highly conserved caspase
protease family, caspase 3. Caspases are key intermediaries of the
apoptotic process, failure of which can lead to cancer [36]. Various
molecular epidemiological studies have suggested that SNPs in
caspases may contribute to cancer risk, and a common coding
variant in caspase 8 has been associated with breast cancer
susceptibility [36,37]. Curiously, apoptosis is also one of the
numerous genomic integrity maintenance functions of BRCA1.
Caspase 3 has been reported to mediate the cleavage of BRCA1
during UV-induced apoptosis, and the cleaved C-terminal
fragment triggers the apoptotic response through activation of
BRCA1 downstream effectors [38]. The rare CNVs disrupting the
DAB2IP and CASP3 genes were both predicted to result in null
alleles (Table 3).
For estrogen, there are multiple lines of evidence for its
profound role in breast cancer development, and disruptions in
estrogen signaling and metabolism have long been considered to
affect breast cancer risk. The estrogen network was largely
explained by the genes under b-estradiol regulation, but two of
the disrupted genes, ESR2 and STRN, had a more straightfor-
ward role in estrogen signalling. ESR2 encodes the estrogen
receptor b, which is one of the main mediators of estrogen
actions within the cell [29]. It binds estrogens with a similar
affinity as estrogen receptor a, and activates expression of
estrogen response element containing genes [39]. ESR2 has
previously been suggested to harbor common breast cancer
predisposing variants [40,41], and ESR2 variation has been
suggested to influence the development of breast cancer also by
in vitro studies [42]. In contrast, striatin acts as molecular scaffold
in non-genomic estrogen-mediated signaling [43]. It physically
interacts with calmodulin 1 [44] and estrogen receptor a,a n d
also forms a complex with protein phosphatase 2A, which also
regulates the function of estrogen receptor a [45]. The
identification of a recurrent deletion allele in CYP2C19, encoding
an enzyme involved in estrogen metabolism [46] and with an
increased frequency in familial cases (Table S2), further
emphasizes the role of estrogen in breast cancer predisposition.
One CYP2C19 allele, CYP2C19*17, defining an ultra-rapid
metabolizer phenotype, has previously been associated with a
decreased risk for breast cancer. This suggests that increased
catabolism of estrogens by CYP2C19 may lead to decreased
estrogen levels and therefore reduced breast cancer risk [47].
Correspondingly, decreased activity of CYP2C19 through
haploinsufficiency might potentially increase the risk of breast
c a n c e r .C u r i o u s l y ,b a s e do nt h e i rf u n c t i o nb o t hESR2 [40,41]
and CYP2C19 [47] have long been considered strong candidate
genes for breast cancer susceptibility. However, no structural
variants have previously been reported in either of them, and it is
possible that CNVs might represent a new class of cancer
predisposing variation in both genes. Functionally relevant
structural variants might be present also in other CYP genes
that locate in gene clusters, like CYP2C19 [48]. The clustering of
similar genes increases the potential for unequal crossing-over
between sister chromatids and thus for creation of CNV alleles.
The genes disrupted in both studied breast cancer cohorts were
also significantly overrepresented among genes connected to
diabetes mellitus. This unexpected result likely represents shared
risk factors predisposing to both breast cancer and diabetes.
Indeed, these two diseases have already been reported to share
several non-genetic risk factors, including obesity and a sedentary
lifestyle. The hormonal factors altered in diabetes include several
hormonal systems that may also affect the development of breast
cancer, including insulin, insulin-like growth factors, and other
growth factors as well as estrogen [49,50]. Our results support
estrogen being the key link in the association between diabetes and
breast cancer, as over one third of the diabetes associated genes in
the two studied breast cancer cohorts were part of the b-estradiol
network.
In conclusion, rare CNVs should be recognized as an
alternative source of genetic variation influencing breast cancer
risk. This notion is further supported by a recent study which also
provided evidence for rare CNVs’ contribution to familial and
early-onset breast cancer [51]. The results from the current
network analysis with two independent breast cancer cohorts
provide strong evidence for the role of estrogen mediated signaling
in breast cancer predisposition and reinforce the concept of TP53
centered tumor suppression in the prevention of malignancy. The
variety of disrupted genes belonging to these networks underscores
that diverse mechanisms are likely to be relevant to breast cancer
pathogenesis.
Materials and Methods
Subjects
The studied familial breast cancer cohort consisted of affected
index cases of 103 Northern Finnish breast, or breast-and ovarian
cancer families. 73 of the families were considered as high risk
ones: 67 had three or more cases of breast cancer, potentially in
combination with single ovarian cancer in first- or second-degree
relatives, and 6 had two cases of breast, or breast and ovarian
cancer in first- or second-degree relatives, of which at least one
with early disease onset (,35 years), bilateral breast cancer, or
multiple primary tumors including breast or ovarian cancer in the
same individual. The remaining 30 families were indicative of
moderate disease susceptibility, and had two cases of breast cancer
in first- or second-degree relatives, of which at least the other
breast cancer was diagnosed under the age of 50. The median at
the age of diagnosis for the familial cases was 49 years (variation
26–89 years), and all families were negative for Finnish BRCA1,
BRCA2, TP53 and PALB2 founder mutations [52].
The studied young breast cancer cohort consisted of 75
Northern Finnish patients that were diagnosed with breast cancer
at or under the age of 40 (median 38, variation 25–40 years).
These patients were unselected for a family history of the disease,
and tested negative for Finnish BRCA1, BRCA2 and PALB2
founder mutations. This independent breast cancer cohort was
collected as a validation group for the studied familial cases, based
on the assumption that when a woman under the age of 40 years
develops breast cancer, a hereditary predisposition may be
suspected regardless whether there is a family history or not
[53]. All biological specimens and clinical information of the
familial and young breast cancer cases investigated were collected
at the Oulu University Hospital, with the written informed consent
of the patients. The geographically and ancestrally matched
control group consisted of 128 anonymous cancer-free female
Northern Finnish Red-Cross blood donors (median age at
monitoring was 56, variation 50–66 years). Permission to use the
above mentioned patient and control materials for studies on
hereditary predisposition to cancer has been obtained from the
Finnish Ministry of Social Affairs and Health (Dnr 46/07/98), and
the Ethical Committee of the Northern-Ostrobothnia Health Care
District (Dnr 88/2000+amendment). All genomic DNA samples
analyzed derived from blood samples extracted using either the
standard phenol-chloroform method, Puregene D-50K purifica-
tion kit (Gentra, Minneapolis, MN, USA), or UltraClean Blood
Rare CNVs Contribute to Hereditary Cancer Risk
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samples from immortalized lymphoblastoid cell lines were used.
CNV discovery with Illumina platform
CNV discovery for both the familial and young breast cancer
cohort as well as for the healthy controls was performed by using
Illumina HumanOmni1-Quad BeadChips (Illumina Inc., San
Diego, CA, USA). This provides high-resolution coverage of the
genome with over one million genetic markers, including those
derived from the 1,000 Genomes Project and all three HapMap
phases, and enables precise definition of the breakpoints. All
samples included in the array had to pass the standard quality
control (QC) measures, which included agarose gel runs to confirm
the integrity of the DNA sample, and accurate concentration
determination with three-step dilution measurements. To control
the confounding effects resulting from the handling of the samples
and subsequent CNV analysis, all cases and controls were given
new IDs and were blindly analyzed without knowing their disease
status. All samples were analyzed following the Illumina provided
protocol in the same laboratory (Laboratory of Cancer Genetics,
University of Oulu) with same arrays at the same period of time,
with random places on the chip.
Samples were analyzed with GenomeStudio Genotyping module
(Illumina) and Nexus Copy Number Discovery Edition 5.1 software
(BioDiscovery Inc., El Segundo, CA, USA). Projects were created in
GenomeStudio, and samples having Call Rates over 98% were
transported to Nexus where samples with quality score ,0.15 were
passed on for further analysis. In order to obtain a high-quality
CNV dataset, we restricted the analysis to CNVs called by two
independent algorithms. In Nexus the SNP-FASST2 segmentation
algorithm was used. The significance threshold was set to 1.0E-06,
and +0.25 for gains and 20.25 for losses. The minimum number of
probes needed for segment calling was set to 25, and minimum loss
of heterozygosity length to 10 000 kb. Quadratic correction was
used as a systematic correction of artifacts caused by GC content
and fragment length. Samples passing all the QCs but showing over
50 copy number changes in Nexus were excluded. The sensitivity of
detection in Nexus was evaluated by analyzing 11 samples
containing known deletions/amplifications confirmed by indepen-
dent methods, and all changes were detected under the parameters
used. All observed CNVs had to be confirmed by Illumina
cnvPartition 2.4.4 software, using a confidence level of over 50 in
order to be included in the analysis: values of 50 or higher tend to
reflect a region with high confidence. The breakpoints of the
observed aberrations were defined using the information obtained
from both Nexus and GenomeStudio, and CNVs that appeared to
be artificially split by the algorithm were joined.
The focus of our interest was on rare duplications and deletions.
Rare events were defined as those which were called by two
independent algorithms and did not overlap over 60% with the
common CNVs in the CNV track defined in Nexus, based on the
Toronto Database of Genomic Variants (DGV). However, as the
DGV database presents several known cancer susceptibility genes
as containing polymorphic CNVs, each CNV not fulfilling the rare
variant criteria were individually inspected before exclusion. As a
result, we decided to include ‘‘common’’ CNV in the rare variant
analysis if fulfilling all three of the following criteria: 1) the CNV
disrupts the involved gene partially, or deletes it entirely, 2)
affected gene is a known breast cancer susceptibility gene, or based
on it biological function it is a highly likely breast cancer
susceptibility gene, and 3) biallelic defects in the involved gene
lead to a rare genomic disorder, indicating that the defective allele
is highly unlikely to be polymorphism. This led to inclusion of
three alleles disrupting the following genes: RECQL4, MCPH1 and
DCLRE1C. All ‘‘rare’’ events which were present at polymorphic
frequencies in the pooled population of 250 cases and controls,
except those that were specific or showed a clear enrichment in
cancer cases, were excluded from further analyses.
All potential events of interest, rare CNV variants, were
validated by another independent method, either by Affymetrix
Genome-Wide Human SNP Array 6.0 platform (Affymetrix,
Santa Clara, CA, USA) or quantitative real time PCR (qPCR).
Affymetrix chip analysis was performed following all the QC
measures recommended by the protocol, and Affymetrix CEL files
were transported to Nexus for analysis with the SNP-FASST2
segmentation algorithm. Confirmation with qPCR was done with
BioRad CFX96 using SsoFast EvaGreen Supermix (BioRad,
Hercules, CA, USA). Samples with rare CNVs and at least 3
wildtype controls were analyzed in triplicate, and quantitation was
done with CFX manager software (version 1.5) under gene
expression analysis. RAD50 and CtIP were used as reference genes.
Statistical analyses
Rare variant carrier frequencies between cancer cases and
controls were compared using Fisher’s exact test. The frequency of
common CNVs and the size of duplications and deletions was
monitored both in cases and controls and tested for differences
with Mann-Whitney U-test (PASW Statistics 18.0 for Windows,
SPSS Inc., Chicago, IL, USA). All tests were two-sided and
considered to be statistically significant with a P-value#0.05.
Network analysis and functional profiling
For pathway and biological function analysis, Ingenuity
Pathway Analysis (IPA, http://www.ingenuity.com/) was used.
The list of disrupted genes [defined as genes (including also their
promoter region) disrupted by the breakpoints or deleted entirely,
and not shared between cases and controls] were uploaded to IPA,
which is an online exploratory tool with a curated database for
over 20,000 mammalian genes and 1.9 million published literature
references. Together with several databases, including Entrez
Gene, Gene Ontology and GWAS database, IPA integrates
transcriptomics data with mining techniques to predict and build
up networks, pathways and biological function clusters. The
software maps the biological relationships of the uploaded genes
according to published literature included in the Ingenuity
database. The output results are given as scores and P-values
computed based on the numbers of uploaded genes in the cluster
or network and the size of network or cluster in the Ingenuity
knowledge database. Benjamini-Hochberg multiple testing cor-
rection P-values (to monitor the false discovery rate) were used to
determine the probability that each biological function or
overrepresentation in diseases is due to change alone. Scores for
IPA networks are the negative logarithm of the P-value, and they
indicate the likelihood of the genes analyzed in a network for being
found together due to random chance. Scores 2 or higher have at
least a 99% likelihood of not being generated by chance alone.
Supporting Information
Figure S1 TP53 and b-estradiol centered network in familial
breast cancer cases. IPA was used to identify the connection
between the genes disrupted in familial breast cancer cases. The
analysis identified a network with TP53 and beta-estradiol (in
green) occupying the central positions. Genes disrupted in breast
cancer cases are coloured with red. Solid lines indicate direct
molecular interaction and dashed lines indicate indirect molecular
interaction.
(JPG)
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breast cancer cases. IPA was used to identify the connection
between the genes disrupted in young breast cancer cases. The
analysis identified a network with TP53 and b-estradiol (in green)
occupying the central positions. Genes disrupted in breast cancer
cases are coloured with red. Solid lines indicate direct molecular
interaction and dashed lines indicate indirect molecular interac-
tion.
(JPG)
Table S1 Novel rare CNVs in genomic DNA that delete or
duplicate genes in breast cancer cases and controls.
(DOC)
Table S2 Novel rare CNVs in genomic DNA that delete or
duplicate genes observed in both breast cancer cases and controls.
(DOC)
Table S3 Novel rare CNVs in genomic DNA that delete or
duplicate genomic regions without annotated genes in breast
cancer cases and controls.
(DOC)
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